Design and evaluation of dihydroisoquinolines as potent and orally bioavailable human cytomegalovirus inhibitors.
Following the identification of first pass metabolism issues with our recently described anti-HCMV compounds, the naphthyridines and isoquinolines, we have designed a class of novel metabolically stable and orally bioavailable anti-HCMV agents, the dihydroisoquinolines.